Formulary implications of management of pulmonary arterial Hypertension: Part II--Payer and provider perspectives on new therapeutic options.
In this two-part white paper from The Pharmacy and Therapeutics Society, the authors have described a number of potent oral therapies available or in late clinical development for the treatment of pulmonary arterial hypertension (PAH). They assert that for optimal clinical efficacy and cost efficiency, patients with PAH should be managed, and treatment initiated, within specialist tertiary referral centers. Combination therapy using oral agents with complementary mechanisms of action may offer increased clinical efficacy over monotherapy and reduce the need for parenteral therapy; however, combination therapy may be limited by clinically significant interaction between these agents, such as in the case of bosentan and sildenafil. Newer treatments may offer less potential for liver damage and more favorable interaction profiles.
Feldman
Jeremy
J
Pulmonary Hypertension Program, St. Joseph's Hospital, Phoenix, USA. jpfeldman1@yahoo.com
Berenbeim
David
D
D005569:Formularies as Topic; D006282:Health Personnel; D006801:Humans; D006976:Hypertension, Pulmonary / Q000188:drug therapy*; D008329:Managed Care Programs; D004364:Pharmaceutical Preparations / Q000191:economics*; D014481:United States
D004364:Pharmaceutical Preparations